Pharmacovigilance

(P-505) Automating Individual Case Safety Report Identification Within Scientific Literature Using Natural Language Processing

(P-001) Signal Detection by Time-to-onset Method in Conjunction with Disproportionality Analysis: A Study of Spontaneous Reports from Japan

(P-002) Risk of First Ischemic Stroke and Use of Antidopaminergic Antiemetics: A Case-time-control Study in France

(P-020) Safety Review of Vemurafenib and Potential Risk of Hyperglycemia: A Systematic Review and Analysis of Individual Case Safety Reports in the WHO Global Database

(P-021) Olanzapine and Potential Risk of Somnambulism : A Systematic Review

(P-029) Assessment of the National Pharmacovigilance System in Nepal Using the Indicator Based Pharmacovigilance Assessment Tool (IPAT)

(P-060) Post-keratoplasty Fungal Keratitis in the Sentinel Distributed Database: Prevalence and Time Trends

(P-061) Montelukast and Nightmare – Further Characterisation Using Data from Vigibase

(P-062) Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study Among Healthcare Professionals and Patients in Croatia, the Netherlands, and the UK

(P-079) Safety of Propofol Use in Children and Adolescents: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS)

(P-081) Assessment of Adherence to Deferasirox Risk Minimization Measures in Saudi Arabia

(P-093) Analysis of Voluntarily Reported Medication Errors: An Excerpt from a Teaching Hospital in a Developing Country

(P-101) A Pharmacovigilance Analysis of Restless Legs Syndrome Treatments and Suicidality

(P-107) Evaluating the Use of Prescription Sequence Symmetry Analysis as a Pharmacovigilance Tool: A Scoping Review

(P-119) Adverse Drug Reactions and Its Evaluation in Saudi Arabia; Retrospective Observational Study

(P-128) Comparisons of Effect Estimates of 12 Prescribing Cascades Using Prescription Sequence Symmetry Analysis

(P-167) Assessment of Drug Related Problems at a Tertiary Care Teaching Hospital

(P-171) Adverse Events Associated with Remdesivir in covid-19 Patients: Evaluation of Spontaneous Reports Submitted to US FDA Adverse Event Reporting System (FAERS)

(P-172) Tocilizumab Induced Adverse Events in covid-19 Patients: Exploration of Reports Submitted to US FDA Adverse Event Reporting System (FAERS)

(P-173) Adverse Events in covid-19 Patients Treated with Lopinavir/ritonavir: Exploration of US FDA Adverse Event Reporting System (FAERS) Reports

(P-175) Community Pharmacists Managed Patient Safety Program with Minimal Patient Contact for Elderly Patients in Ajman, United Arab Emirates

(P-176) Identification of Novel Safety Signals of sglt2 Inhibitors: Analysis of Us Fda and Global Safety Databases

(P-177) Identification of Novel Safety Signals of sglt2 Inhibitors: A Pharmacovigilance Analysis of the Usfda and Global Adverse Event Reporting Databases

(P-196) Estimation of Adverse Events Scale Relating Korean Medicine in Korea

(P-200) Safety Evaluation of Panobinostat, Ixazomib, Elotuzumab, and Daratumumab Using FDA Adverse Event Reporting System (FAERS) Database 2015 – 2020

(P-206) Pediatric Fentanyl Overdose Within an Electronic Health Record Database

(P-259) A Systematic Review of Non-small Cell Lung Cancer Treatment-related Cardiotoxicity

(P-265) Detecting Tizanidine and cyp1a2 Inhibitor Interaction Signals Using the Food and Drug Administration’s Adverse Event Reporting System

(P-267) Excess Risk of Anaphylaxis with Concomitant Use of Qingkailing Injection and Cefotaxime Sodium: An Example of Novel Herbal-drug Interaction

(P-274) Detecting Drug-drug Interaction Signal of Concomitant Use of Tramadol and SSRI Using Korea Adverse Event Reporting System Database

(P-278) A Review of the Sampling Methodology Used in Studies Evaluating the Effectiveness of Risk Minimization Measures in Europe

(P-289) Drug-induced Liver Injury Associated with Lopinavir-ritonavir in Patients with COVID-19: A Disproportionality Analysis of U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) Data

(P-294) Risk of Fracture Associated with SGLT-2 Inhibitors as an Add-on Therapy to Metformin in Patients with Type 2 Diabetes Mellitus

(P-297) Trastuzumab Related Cardiotoxicity in Breast Cancer

(P-300) Zolpidem, Zopiclone and Zaleplon Induce Complex Sleep Behaviors

(P-303) Cardiovascular Safety Assessment of Febuxostat and Allopurinol in the Real World: A Retrospective Cohort Study

(P-307) Evaluation of Availability of Information on Risk Factors in Reports of Adverse Drug Reactions in a Pharmacovigilance Database

(P-309) Psoriasis Risk After Betablockers Exposure: Analysis of French Pharmacovigilance Data

(P-323) Risk of Cardiovascular Diseases Associated with Sulfonylurea as an Add-on Therapy to Metformin in Patients with Type 2 Diabetes Mellitus

(P-331) Evaluation of Potential Drug-drug Interactions Among Patients of the Nephrology and Kidney Transplant Wards of a Major Teaching Hospital

(P-345) A Comparison of Data Mining Algorithms Using Different Drug Classifications for Signal Identification

(P-346) Periodic Safety Reporting System for Post-market Drug Safety: A Comparative Analysis of Europe, United States, Japan and Korea

(P-362) Post-marketing Drug Safety Sources: An Evaluation of the Fda’s Drug Safety Communications

(P-363) Assessing the Post Marketing Experience of Clopidogrel and Major Cardiovascular Events After PCI in Saudi Arabia Using the Saudi Food and Drug Authority (SFDA) Spontaneous Reporting System

(P-364) The Establishment of Regional Pharmacovigilance (PV) Centers in Saudi Arabia

(P-365) A Tenfold Increase in the Rate of Adverse Drug Event Reports in Saudi Arabia

(P-366) Trajectories of Corticosteroid Dosing Pattern Among Patients with Systemic Lupus Erythematosus

(P-373) Cefoperazone and the Risk of Bleeding: A Systematic Review and Network Meta-analysis

(P-375) Remdesivir Safety Monitoring During the COVID-19 Pandemic: A Global Review of Adverse Drug Reaction (ADR) Reporting in Vigibase

(P-376) Dupilumab Use and Potential Risk of Alopecia Areata: A Systematic Review

(P-378) A Counterfactual Approach to Minimize Channeling Bias in Post-market Safety Surveillance

(P-381) Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)

(P-383) Adverse Reactions to Dolutegravir Reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa

(P-387) Individual Case Safety Reports Analysis for Patients with Diabetes Mellitus on Insulin in Africa and the Middle East

(P-419) Comparative Risk of Delirium Associated with Oxybutynin and Solifenacin in Older Adults

(P-435) Comparison of Safety Signals Between Selective Serotonin-reuptake Inhibitors (SSRI) and Serotonin–norepinephrine Reuptake Inhibitors (SNRI) Employing Fda Adverse Event Reporting System (FAERS) Database

(P-436) Review of Sytemic Adverse Drug Reactions of Vascular Endothelial Growth Factor Inhibitors in French Pharmacovigilance Data Base

(P-442) Medication Error Concept and Reporting Practices in Saudi Arabia: A Nationwide Study Among Healthcare Professionals

(P-443) Teratogenicity Associated with Antibiotic Therapy; A Disproportionality Analysis in Spontaneous Reporting Database

(P-468) Biliary Toxicity of Immune Checkpoint Inhibitors: A Pharmacovigilance Study Through FDA Adverse Event Reporting System Database

(P-489) Evaluation of Chirality for Withdrawn Drugs

(P-528) Measuring the Impact of Marketing Authorisation Withdrawal and Revocation on Public Health in France, Germany and UK

(P-547) Aromatase Inhibitors Associated with Sjogren’s Syndrome: A Disproportionality Analysis in Spontaneous Reporting Database

(P-549) Benzodiazepine Use, Nonmedical Use, and Overdose in the U.S

(P-553) Pharmacists Role in Patient Safety: Evaluation of Dispensing Errors in a Regional Hospital

(P-566) Reporting of Pancreatitis with Tocilizumab Use: A Disproportionality Analysis Using the United States Food and Drug Administration Adverse Event Reporting System